PMID- 35179762
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20220407
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 26
IP  - 3
DP  - 2022 Feb
TI  - Nivolumab as a bridge to allogeneic hematopoietic stem cell transplantation is 
      associated with improved survival.
PG  - 957-965
LID - 28005 [pii]
LID - 10.26355/eurrev_202202_28005 [doi]
AB  - OBJECTIVE: The aim of the present study was to compare the effects of nivolumab 
      bridge to allogeneic hematopoietic stem cell transplantation (allo-SCT) on 
      progression-free survival (PFS) and overall survival (OS) and toxicity profile. 
      PATIENTS AND METHODS: The study population consisted of relapsed/refractory cases 
      of HL, who were treated with nivolumab for disease control and subsequently 
      underwent allo-SCT at our institution. The control group consisted of HL patients 
      who relapsed or refractory after multiple lines of therapy and underwent allo-SCT 
      without nivolumab before transplantation as bridging therapy. RESULTS: The 
      incidence of acute and chronic graft vs. host disease (GVHD) was similar in both 
      groups. The 100-day mortality occurred in 1 patient (10%) in the nivolumab group 
      and 4 patients (16.7%) in the control group (p = 0.54). During 30-month 
      follow-up, PFS was achieved in 60% of patients in the nivolumab group and 45.8% 
      in the control group (p = 0.69). OS during 30-month follow-up was 80% in the 
      nivolumab group and 41.7% in the control group, OS was superior in patients in 
      the nivolumab group than in the control group (p = 0.04). CONCLUSIONS: Allo-SCT 
      after bridging therapy with nivolumab provides a survival advantage over patients 
      who underwent allo-SCT without the bridging. Therapy with nivolumab in 
      combination with post-transplant cyclophosphamide does not appear to increase 
      GVHD.
FAU - Iskender, D
AU  - Iskender D
AD  - Department of Hematology and Hematopoietic Stem Cell Transplantation unit, Dr. 
      Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, 
      Turkey. diclekoca@yahoo.com.
FAU - Cakar, M K
AU  - Cakar MK
FAU - Dal, M S
AU  - Dal MS
FAU - Baysal, N A
AU  - Baysal NA
FAU - Merdin, A
AU  - Merdin A
FAU - Bakirtas, M
AU  - Bakirtas M
FAU - Ulu, B U
AU  - Ulu BU
FAU - Basci, S
AU  - Basci S
FAU - Yigenoglu, T N
AU  - Yigenoglu TN
FAU - Altuntas, F
AU  - Altuntas F
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Disease-Free Survival
MH  - *Graft vs Host Disease
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Nivolumab/therapeutic use
MH  - Progression-Free Survival
MH  - Retrospective Studies
MH  - Transplantation, Homologous
EDAT- 2022/02/19 06:00
MHDA- 2022/04/08 06:00
CRDT- 2022/02/18 12:15
PHST- 2022/02/18 12:15 [entrez]
PHST- 2022/02/19 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
AID - 28005 [pii]
AID - 10.26355/eurrev_202202_28005 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2022 Feb;26(3):957-965. doi: 
      10.26355/eurrev_202202_28005.